CE-123

CE-123
	(S)-CE-123
Clinical data
Other names	(S)-CE-123; S-CE-123
Legal status
Legal status	UK: Under Psychoactive Substances Act;
Identifiers
	IUPAC name (S)-5-(benzhydrylsulfinylmethyl)-1,3-thiazole;
CAS Number	1879038-73-9 ; (S)-CE-123: 2378384-49-5;
PubChem CID	118871455;
ChemSpider	110407278;
UNII	2P6T8SD99L;
ChEMBL	ChEMBL4456176;
Chemical and physical data
Formula	C17H15NOS2
Molar mass	313.43 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=S(Cc1cncs1)C(c2ccccc2)c3ccccc3;
	InChI InChI=1S/C17H15NOS2/c19-21(12-16-11-18-13-20-16)17(14-7-3-1-4-8-14)15-9-5-2-6-10-15/h1-11,13,17H,12H2; Key:VBBBWHDWYLUSEL-UHFFFAOYSA-N;

CE-123, or as the active enantiomer (S)-CE-123, is an analog of modafinil, the most researched of a series of structurally related heterocyclic derivatives.^[1]^[2]^[3] In animal studies, CE-123 was found to improve performance on tests of learning and memory in a manner consistent with a nootropic effect profile.^[4]^[5]^[6]^[7] (S)-CE-123 has pro-motivational effects in animals, reverses tetrabenazine-induced motivational deficits, and could be useful in the treatment of motivational disorders in humans.^[8]^[9]

References

^ Sase A, Aher YD, Saroja SR, Ganesan MK, Sase S, Holy M, et al. (March 2016). "A heterocyclic compound CE-103 inhibits dopamine reuptake and modulates dopamine transporter and dopamine D1-D3 containing receptor complexes". Neuropharmacology. 102: 186–96. doi:10.1016/j.neuropharm.2015.07.039. PMID 26407764. S2CID 19840397.
^ Saroja SR, Aher YD, Kalaba P, Aher NY, Zehl M, Korz V, et al. (October 2016). "A novel heterocyclic compound targeting the dopamine transporter improves performance in the radial arm maze and modulates dopamine receptors D1-D3". Behavioural Brain Research. 312: 127–37. doi:10.1016/j.bbr.2016.06.011. PMID 27288589. S2CID 38509577.
^ Hussein AM, Aher YD, Kalaba P, Aher NY, Dragačević V, Radoman B, et al. (August 2017). "A novel heterocyclic compound improves working memory in the radial arm maze and modulates the dopamine receptor D1R in frontal cortex of the Sprague-Dawley rat". Behavioural Brain Research. 332: 308–315. doi:10.1016/j.bbr.2017.06.023. PMID 28629964. S2CID 205895268.
^ Nikiforuk A, Kalaba P, Ilic M, Korz V, Dragačević V, Wackerlig J, et al. (2017). "A Novel Dopamine Transporter Inhibitor CE-123 Improves Cognitive Flexibility and Maintains Impulsivity in Healthy Male Rats". Frontiers in Behavioral Neuroscience. 11: 222. doi:10.3389/fnbeh.2017.00222. PMC 5711856. PMID 29230168.
^ Kristofova M, Aher YD, Ilic M, Radoman B, Kalaba P, Dragacevic V, et al. (May 2018). "A daily single dose of a novel modafinil analogue CE-123 improves memory acquisition and memory retrieval". Behavioural Brain Research. 343: 83–94. doi:10.1016/j.bbr.2018.01.032. PMID 29410048. S2CID 3551334.
^ Camats-Perna J, Kalaba P, Ebner K, Sartori SB, Vuyyuru H, Aher NY, et al. (2019). "Differential Effects of Novel Dopamine Reuptake Inhibitors on Interference With Long-Term Social Memory in Mice". Frontiers in Behavioral Neuroscience. 13: 63. doi:10.3389/fnbeh.2019.00063. PMC 6470289. PMID 31031603.
^ Rotolo RA, Dragacevic V, Kalaba P, Urban E, Zehl M, Roller A, et al. (2019). "(S)-CE-123 Partially Reverses the Effort-Related Effects of the Dopamine Depleting Agent Tetrabenazine and Increases Progressive Ratio Responding". Frontiers in Pharmacology. 10: 682. doi:10.3389/fphar.2019.00682. PMC 6611521. PMID 31316379.
^ Salamone JD, Correa M (January 2024). "The Neurobiology of Activational Aspects of Motivation: Exertion of Effort, Effort-Based Decision Making, and the Role of Dopamine". Annu Rev Psychol. 75: 1–32. doi:10.1146/annurev-psych-020223-012208. hdl:10234/207207. PMID 37788571.
^ Rotolo RA, Dragacevic V, Kalaba P, Urban E, Zehl M, Roller A, Wackerlig J, Langer T, Pistis M, De Luca MA, Caria F, Schwartz R, Presby RE, Yang JH, Samels S, Correa M, Lubec G, Salamone JD (2019). "The Novel Atypical Dopamine Uptake Inhibitor (S)-CE-123 Partially Reverses the Effort-Related Effects of the Dopamine Depleting Agent Tetrabenazine and Increases Progressive Ratio Responding". Front Pharmacol. 10: 682. doi:10.3389/fphar.2019.00682. PMC 6611521. PMID 31316379.

[1] Sase A, Aher YD, Saroja SR, Ganesan MK, Sase S, Holy M, et al. (March 2016). "A heterocyclic compound CE-103 inhibits dopamine reuptake and modulates dopamine transporter and dopamine D1-D3 containing receptor complexes". Neuropharmacology. 102: 186–96. doi:10.1016/j.neuropharm.2015.07.039. PMID 26407764. S2CID 19840397.

[2] Saroja SR, Aher YD, Kalaba P, Aher NY, Zehl M, Korz V, et al. (October 2016). "A novel heterocyclic compound targeting the dopamine transporter improves performance in the radial arm maze and modulates dopamine receptors D1-D3". Behavioural Brain Research. 312: 127–37. doi:10.1016/j.bbr.2016.06.011. PMID 27288589. S2CID 38509577.

[3] Hussein AM, Aher YD, Kalaba P, Aher NY, Dragačević V, Radoman B, et al. (August 2017). "A novel heterocyclic compound improves working memory in the radial arm maze and modulates the dopamine receptor D1R in frontal cortex of the Sprague-Dawley rat". Behavioural Brain Research. 332: 308–315. doi:10.1016/j.bbr.2017.06.023. PMID 28629964. S2CID 205895268.

[4] Nikiforuk A, Kalaba P, Ilic M, Korz V, Dragačević V, Wackerlig J, et al. (2017). "A Novel Dopamine Transporter Inhibitor CE-123 Improves Cognitive Flexibility and Maintains Impulsivity in Healthy Male Rats". Frontiers in Behavioral Neuroscience. 11: 222. doi:10.3389/fnbeh.2017.00222. PMC 5711856. PMID 29230168.

[5] Kristofova M, Aher YD, Ilic M, Radoman B, Kalaba P, Dragacevic V, et al. (May 2018). "A daily single dose of a novel modafinil analogue CE-123 improves memory acquisition and memory retrieval". Behavioural Brain Research. 343: 83–94. doi:10.1016/j.bbr.2018.01.032. PMID 29410048. S2CID 3551334.

[6] Camats-Perna J, Kalaba P, Ebner K, Sartori SB, Vuyyuru H, Aher NY, et al. (2019). "Differential Effects of Novel Dopamine Reuptake Inhibitors on Interference With Long-Term Social Memory in Mice". Frontiers in Behavioral Neuroscience. 13: 63. doi:10.3389/fnbeh.2019.00063. PMC 6470289. PMID 31031603.

[7] Rotolo RA, Dragacevic V, Kalaba P, Urban E, Zehl M, Roller A, et al. (2019). "(S)-CE-123 Partially Reverses the Effort-Related Effects of the Dopamine Depleting Agent Tetrabenazine and Increases Progressive Ratio Responding". Frontiers in Pharmacology. 10: 682. doi:10.3389/fphar.2019.00682. PMC 6611521. PMID 31316379.

[SalamoneCorrea2024-8] Salamone JD, Correa M (January 2024). "The Neurobiology of Activational Aspects of Motivation: Exertion of Effort, Effort-Based Decision Making, and the Role of Dopamine". Annu Rev Psychol. 75: 1–32. doi:10.1146/annurev-psych-020223-012208. hdl:10234/207207. PMID 37788571.

[RotoloDragacevicKalaba2019-9] Rotolo RA, Dragacevic V, Kalaba P, Urban E, Zehl M, Roller A, Wackerlig J, Langer T, Pistis M, De Luca MA, Caria F, Schwartz R, Presby RE, Yang JH, Samels S, Correa M, Lubec G, Salamone JD (2019). "The Novel Atypical Dopamine Uptake Inhibitor (S)-CE-123 Partially Reverses the Effort-Related Effects of the Dopamine Depleting Agent Tetrabenazine and Increases Progressive Ratio Responding". Front Pharmacol. 10: 682. doi:10.3389/fphar.2019.00682. PMC 6611521. PMID 31316379.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

CE-123

See also

References